A nurse is preparing to administer methylergonovine to a client who is 2 hr postpartum and has a boggy fundus. Which of the following findings should the nurse identify as a contraindication to this medication?

An ST-elevation myocardial infarction(STEMI) occurs when a coronary artery is completely occluded, leading to transmural myocardial ischemiaand necrosis. This medical emergency is identified by specific ECG changes and elevated cardiac biomarkerslike Troponin I (> 0.03 ng/mL). Immediate pharmacologic intervention focuses on reperfusion, preventing further thrombus propagation, and reducing myocardial oxygen demand to preserve functional cardiac tissue.

Rationale:

A. Heparin is an anticoagulant indicated in the acute phase of a STEMI to prevent the formation and extension of fibrin clots. By accelerating the action of antithrombin 3, it neutralizes thrombin and factor Xa. This prevents further occlusion of the coronary artery while the patient awaits definitive reperfusion therapy like percutaneous coronary intervention.

B. Digoxin is a positive inotrope and negative chronotrope primarily used for chronic heart failure or atrial fibrillation with rapid ventricular response. In the setting of an acute STEMI, it is generally avoided because it increases myocardial oxygen consumptionby increasing contractility. Excessive oxygen demand during an active infarction can exacerbate myocardial injury and extend the area of necrosis.

C. Aspirin is a cornerstone of acute coronary syndrome management due to its immediate antiplatelet effects. It irreversibly inhibits cyclooxygenase-1, preventing the synthesis of thromboxane A2, which is a potent stimulator of platelet aggregation. Administering aspirin early significantly reduces mortality by limiting the size of the developing thrombus within the obstructed coronary vessel.

D. Morphine is the preferred analgesic for managing the crushing chest pain associated with myocardial infarction when nitrates are insufficient. Beyond pain relief, it provides beneficial hemodynamic effectsby reducing preload through venous dilation and decreasing systemic vascular resistance. These actions lower the myocardial workload and oxygen demand, while also alleviating the patient's anxiety and sympathetic surge.

E. Dopamine is a sympathomimetic amine used for hemodynamic support in cases of cardiogenic shock or clinically significant hypotension. The client's blood pressure is currently stable at 126/80 mm Hg, making a vasopressor or potent inotrope unnecessary and potentially harmful. Administering dopamine in a stable STEMI patient would unnecessarily increase heart rate and myocardial metabolic demand, worsening the ischemia.

Atorvastatin is an HMG-CoA reductase inhibitorthat lowers cholesterol by blocking the rate-limiting step of hepatic cholesterol synthesis. Its primary therapeutic goal is the reduction of atherogenic lipoproteinsto prevent cardiovascular disease and stroke. Effective therapy is measured by a significant improvement in the lipid profile, specifically targeting the reduction of low-density lipoproteins(LDL).

Rationale:

A.Decreased HDL levels would indicate a worsening of the patient's cardiovascular risk profile rather than effective treatment. High-density lipoprotein (HDL) is considered "good" cholesterol because it helps remove other forms of cholesterol from the bloodstream. A successful response to statin therapy would involve maintaining or slightly increasing HDL levels to provide better cardioprotective benefits.

B.Increased serum transaminase levels are an adverse effect of atorvastatin indicating potential hepatotoxicity, not therapeutic effectiveness. Statins are metabolized by the liver and can occasionally cause inflammation or damage to hepatocytes. If these enzymes (AST and ALT) rise significantly, the nurse must report this finding as it may necessitate the discontinuation of the medication.

C.Decreased LDL levels are the hallmark indicator of effective atorvastatin therapy. Low-density lipoprotein is the primary target for statins because it contributes to plaque buildup in the arteries, leading to atherosclerosis. A significant reduction in LDL proves that the HMG-CoA reductase inhibitor is successfully lowering the production of harmful cholesterol and reducing overall cardiovascular risk.

D.Increased creatine kinase (CK) levels are a laboratory marker for muscle damage and a sign of a serious adverse effect called rhabdomyolysis. This condition involves the breakdown of skeletal muscle fibers, which can lead to acute renal failure. Elevated CK levels are a reason for concern and immediate clinical intervention, not a sign that the cholesterol-lowering treatment is working.